The Leading Source for Pharmaceutical & Biopharmaceutical Manufacturing News
FREE Daily Email Newsletter
Dynamic Batching Station
May 8, 2013 3:31 pm | Product Releases | CommentsThe Dynamic Batching Station (DBS) is a skidded process module for batching dry powders into liquids. It can be fed dry powders or granular sugar from bulk trucks, bulk bags or other feed options. The fully automated process can operate as a “batch and pump” or “continuous steady state” and other operating modes.
Prostate Test Could Cut Need for Surgery
May 8, 2013 1:46 pm | by Wall Street Journal | Videos | CommentsA new genetic test can help distinguish between aggressive and low-risk forms of prostate cancer, which could enable many men to delay or forgo surgery to treat it. Over 220,000 men in the U.S. are diagnosed with prostate cancer anually.
Merck: FDA Reviewing its Ragweed Allergy Therapy
May 8, 2013 12:47 pm | by The Associated Press | News | CommentsWHITEHOUSE STATION, N.J. (AP) — Drugmaker Merck & Co. says the Food and Drug Administration is reviewing its second application to sell a new type of allergy treatment meant to gradually reduce allergic reactions over time, rather than just relieving sneezing, itching and other symptoms...
ProcessPro Launches Major Rebrand
May 8, 2013 12:14 pm | News | CommentsProcessPro, mid-market ERP software solution for process manufacturers, today announced a total brand review and with the unveiling of a new logo and tagline to support its evolution within the industry. The brand review also entails a website reveal scheduled tentatively for June 2013.
Cabinet U-Handles
May 8, 2013 10:15 am | Product Releases | CommentsThe EN 628.4 Cabinet U-Handles with Power Switching Function is available in metric sizes. These RoHS compliant U-handles feature a push button that allows two switching positions. The status is displayed by two LEDs, red or green. The red LED will be lit during normal function.
Huahai and Oncobiologics Create Broad Biosimilars Partnership
May 8, 2013 9:34 am | News | CommentsOncobiologics, Inc. announced today that Zhejiang Huahai Pharmaceutical Co., Ltd and Oncobiologics have signed an alliance agreement for the development, manufacture and commercialization of biosimilar monoclonal antibody products. The scope of the agreement includes exclusive commercialization by Huahai of four biosimilars developed by Oncobiologics and manufactured in China at a Huahai biologics facility for the China market
Automated Loop Filling Module
May 8, 2013 9:17 am | Product Releases | CommentsThe FlowSyn Auto-LF loop filling module is a powerful and highly efficient module that allows chemists to automatically perform in sequence combinatorial flow chemistry experiments. Each experiment can be run under different conditions and utilise a different set of reagents or monomers.
Giant, Meningitis-Carrying Snails Turn Up in Texas
May 8, 2013 8:31 am | Videos | CommentsScientists are warning residents of Houston, Texas, not to handle giant African land snails, which have been spotted in neighborhood gardens, because they can carry meningitis. The snails also carry other diseases which can cause sickness and even death.
Gene Test May Help Guide Prostate Cancer Treatment
May 8, 2013 8:20 am | by MARILYNN MARCHIONE,AP Chief Medical Writer | News | CommentsA new genetic test to gauge the aggressiveness of prostate cancer may help tens of thousands of men each year decide whether they need to treat their cancer right away or can safely monitor it. The new test, which goes on sale today, joins another one that recently came on the market. Both analyze multiple genes in a biopsy sample and give a score for aggressiveness, similar to tests used now for certain breast and colon cancers.
Ariad Reports $6.4M in First Quarter Sales of Leukemia Pill
May 8, 2013 8:13 am | News | CommentsAriad Pharmaceuticals Inc. said Tuesday that revenue from its leukemia pill Iclusig, its first approved drug, totaled $6.4 million in the first quarter, surpassing Wall Street's expectations. The Food and Drug Administration approved Iclusig in December as a treatment for two types of the disease.
Cubist Antibiotic Regimen Gets Fast-Track Review
May 8, 2013 8:10 am | News | CommentsCubist Pharmaceuticals Inc. said Tuesday that the Food and Drug Administration has given fast-track status to an experimental antibiotic regimen as a treatment for three types of infections. The company is studying a combination of ceftolozane and tazobactam as a treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia as well as complicated urinary-tract infections.
Takeda to Acquire Inviragen, Inc.
May 8, 2013 8:04 am | News | CommentsTakeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced today that Takeda, its wholly owned subsidiary Takeda America Holdings, Inc., and Inviragen, Inc. have entered into a definitive agreement for Takeda to acquire Inviragen for an upfront payment of US$35 million, and future payments of up to US$215 million linked to the progress of clinical development and achievement of key commercial milestones.
Vegas Jury Asked to Ignore Hep C Case 'Hysteria'
May 8, 2013 7:59 am | by KEN RITTER,Associated Press | News | CommentsJurors will have to decide if a former endoscopy clinic owner and employees knew they were committing a crime, or if they simply made mistakes when seven of their patients became infected with incurable hepatitis C in 2007 — including one patient who later died, defense attorneys said Tuesday.
WebMD CEO Redmond Steps Down
May 7, 2013 6:37 pm | by The Associated Press | News | CommentsWebMD Health Corp. said Tuesday that CEO Cavan Redmond is leaving the company after less than a year on the job. Redmond is stepping down as CEO and from the board of directors effective immediately. David Schlanger, WebMD's head of strategic and corporate development, will take over as interim...
Baxter Says Promising Alzheimer’s Treatment Has Failed In Late-Stage Clinical Trial
May 7, 2013 2:32 pm | by ANDREW POLLACK, New York Times News Service | News | CommentsIn yet another setback for the treatment of Alzheimer’s disease, Baxter said that a promising new therapy had failed to halt the mental decline caused by the disease in a late-stage clinical trial. Prospects that the drug might have some effect brightened last year when researchers reported that four patients who had received the maximum dose had gone three years without any decline in several measures of cognition and daily functioning,
